8-K: Allakos Inc. Announces Restructuring and Provides Update on Clinical Programs

Allakos Inc. is halting development of lirentelimab, reducing its workforce by almost 50%, and focusing on its AK006 program, while also providing updates on recent clinical trial results.

Summary

• Allakos Inc. has announced a restructuring that includes halting all lirentelimab-related activities.
• The company is reducing its workforce by almost 50%.
• The restructuring is expected to result in $30 million in closeout, severance, and other costs.
• The company estimates net cash used in operating activities for 2024 to be between $85 and $90 million, or $55 to $60 million excluding restructuring costs.
• Allakos expects to have a cash runway into the middle of 2026.
• The company is shifting its focus to the AK006 program, which targets Siglec-6, a more potent inhibitory receptor than Siglec-8.
• Phase 2 clinical trial results for lirentelimab in atopic dermatitis (ATLAS) and chronic spontaneous urticaria (MAVERICK) were presented, showing no statistically significant results for the primary endpoints.
• The company is progressing with Phase 1 trials for AK006, with data expected throughout 2024.

Sentiment

Score: 3

Explanation: The document contains significant negative news including the halting of a major program and a large workforce reduction. While the focus on AK006 is a positive, the overall sentiment is negative due to the restructuring and failed trials.

Positives

• The company is focusing on AK006, which targets a more potent inhibitory receptor (Siglec-6) than the previous target (Siglec-8).
• Preclinical studies show AK006 has stronger mast cell inhibition than AK002.
• The company has a cash runway into the middle of 2026, providing time to advance the AK006 program.
• The company is progressing with Phase 1 trials for AK006 with multiple data readouts expected in 2024.

Negatives

• The company is halting all lirentelimab-related activities, which represents a significant change in strategy.
• The company is reducing its workforce by almost 50%, which will impact employees.
• The ATLAS and MAVERICK Phase 2 trials for lirentelimab did not meet their primary endpoints.
• The company will incur $30 million in restructuring costs.

Risks

• The company's future is heavily reliant on the success of the AK006 program.
• There are risks associated with clinical trials, including the ability to demonstrate safety and efficacy.
• The company may need to raise additional capital in the future.
• The company operates in a competitive and rapidly changing environment.

Future Outlook

The company is focused on advancing the AK006 program, with multiple data readouts expected throughout 2024. The company anticipates a cash runway into the middle of 2026.

Management Comments

• The company is halting lirentelimab-related activities to focus on the AK006 program.
• The company believes Siglec-6 is a more potent target than Siglec-8.
• The company is reducing its workforce to conserve capital.

Industry Context

The announcement reflects a shift in strategy for Allakos, moving away from lirentelimab after disappointing clinical trial results and focusing on a new target with AK006. This is not uncommon in the biotech industry where companies must adapt to clinical trial outcomes and prioritize promising programs.

Comparison to Industry Standards

• The failure of lirentelimab to meet primary endpoints in Phase 2 trials is not uncommon in drug development, where many candidates fail to show efficacy.
• The decision to halt a program and restructure is a common response to negative clinical data, as seen with other biotech companies such as Achaogen and Omeros.
• The focus on a new target (Siglec-6) and a new drug candidate (AK006) is a typical pivot strategy in the biotech industry, similar to how companies like Vertex have shifted focus after setbacks.
• The estimated cash runway into mid-2026 is a critical metric for investors, as it indicates the company's ability to fund operations and development programs without needing immediate capital raises, similar to how companies like BioMarin and Sarepta manage their cash reserves.

Stakeholder Impact

• Shareholders will be impacted by the change in strategy and the negative clinical trial results.
• Employees will be impacted by the workforce reduction.
• Patients who were hoping for a treatment with lirentelimab will be impacted by the program being halted.
• Suppliers and other business partners may be impacted by the restructuring.

Next Steps

• Complete SAD and MAD dosing with IV AK006 in healthy volunteers in Q1 2024.
• Initiate the randomized, double-blind, placebo-controlled SC AK006 cohort in healthy volunteers in Q1 2024.
• Report SAD and MAD safety, PK, and PD results from the Phase 1 IV AK006 trial in Q2 2024.
• Initiate the Phase 1 trial of IV AK006 in patients with CSU in Q2 2024.
• Report SC AK006 safety, PK, and PD results from the Phase 1 trial in Q3 2024.
• Report topline data from the Phase 1 trial of IV AK006 in patients with CSU by year-end 2024.

Key Dates

Keywords

AK006, lirentelimab, Siglec-6, Siglec-8, mast cell, atopic dermatitis, chronic spontaneous urticaria, clinical trials, restructuring, biotechnology